Cancer biomarker detection is used using artificial intelligence.
REPUBLIKA.CO.ID, JAKARTA — Pandu Raharja Liu (28 years old) has successfully developed artificial intelligence technology (AI).artificial intelligence/AI) to detect cancer biomarker profiles. Thanks to his innovation, Pandu was included in the Forbes 30 Under 30-Europe 2022 list for the Science and Health category (Forbes 30 Under 30-Europe 2022: Science and Healthcare).
Two custom software Panakeia has also received approval from British and European Union authorities.”Pandu Raharja-Liu uses artificial intelligence to generate profiles cancer biomarkers in minutes, not days, speeding up diagnosis, treatment, and drug development.” Forbes.
Panakeia was founded in November 2018. Pandu met with Pahini Pandya, who is currently the co-founder and CEO of Panakeia, at Entrepreneur First London.
“She is cancer biologist, I’m AI researcher. In the past, I have done a lot of cancer research in terms of computational and AI,” said the man who graduated from the Technical University of Munich.
Breakthrough
Panakeia developed the first approach that can detect cancer biomarker profiles with the help of AI technology without having to perform tests. Pandu believes it is a breakthrough.
Pandu explained, the journey of cancer diagnosis usually starts from the symptoms felt by the patient or felt during screening. Then, the hospital performs gross detection using radiographic technology, such as CT, MRI, and Pet.
Next, a biopsy sample is taken. Next is the primary analysis by the pathologist. After that, biomarker profiling is performed to determine specific cancer/cancer prognosis/treatment recommendations. Lastly is the tumor board, where oncologists, radiologists, pathologists, and surgeons meet to discuss treatment plans.
